AQ Lab beta testing completed and the platform is ready for commercial deployment
After a year of development and a few months of final beta testing, AQ Lab is ready to be deployed as a research and development platform for E-TRF and biosensor-based projects.
Turku, Finland. Aqsens Health’s AQ Lab platform enables users to perform high-quality research using the company’s E-TRF and biosensor technologies. The platform was developed to help Aqsens Health manage overseas projects and to ensure that all projects meet Aqsens Health’s quality standards, while also bringing efficiency to collaborative research work. AQ Lab implements modern web architectures making it easily deployable to any global cloud environments.
As a platform it guides users step-by-step through Aqsens Health’s research processes from sample pretreatment, biosensor development and chemical sensor screening to assay protocols, providing the means for fluent project management within different teams and organizations. The built-in checks ensure that all parts of the development framework are completed according to Aqsens Health’s procedures and standards.
AQ Lab also includes integrated analytical tools that help assess sensor functionality and assay results. It makes sure that quality control and data points are evaluated properly and has an audit trail, so all the necessary data is gathered from research work to ensure high quality results. Through the online feedback channel Aqsens Health’s team can provide quick support and ensure that research projects progress as planned and meet all Aqsens Health’s research quality requirements.
“Developing AQ Lab has been a really fascinating project. Building a collaborative web environment for an industry which traditionally has not been that collaborative is always an intriguing challenge,” says Goodhum Oy’s CEO Mikko Kämäräinen, who has had an integral part in the platform development.
“In the development process we used our iterative design process with emphasis on ease of use and simplicity. Because of the platform’s modular application structure it is easy to further develop and to add for example AI capabilities provided by external parties,” Kämäräinen continues.
A research team at Noguchi Memorial Institute for Medical Research (NMIMR) in Accra, Ghana, has been testing the platform this fall with a malaria saliva sample set.
“We have been beta testing AQ LAB at the NMIMR since September and after minor improvements we found it a very dynamic way to perform research work, and more importantly it is user friendly and facilitates efficient analysis,” says Research Assistant Jasmine Dowuona from the Noguchi Memorial Institute for Medical Research.
The AQ Lab platform makes managing Aqsens Health’s overseas collaborative projects easier according to Aqsens Health’s Head of Laboratory Vilhelmiina Juusti.
“Having a web-platform that implements our E-TRF and biosensor development processes is critical in enabling us to successfully manage our projects in Finland, and especially in China and Ghana,” says Aqsesn Health’s Head of the Laboratory Vilhelmiina Juusti.
“AQ Lab will guarantee high quality research and also bring with it new opportunities for scaling our business with third parties,” Juusti concludes.
AQ Lab will first be used as a project management platform for Aqsens Health’s projects both in Finland and overseas. The aim is to later open the platform to third party collaboration and for researchers or teams who are interested in non-invasive sample analysis and the possibility of discovering new biomarkers.
Download the press release here.
For more information, contact:
CEO and Co-Founder
Timo Teimonen
+358 40 5853105 | timo.teimonen@aqsens.com
Aqsens Health Oy is a Finnish medtech startup developing non-invasive screening tests for high-impact diseases. The company’s research projects focus on developing saliva-based infectious disease detection fit for the needs of developing economies, and establishing an accurate and cost-efficient urine-based screening test for urinary tract cancers. The tests use Aqsens Health’s novel E-TRF method in combination with phage-biosensors.
